The Markey Cancer Center (MCC) Cancer Research Informatics (CRI) Shared Resource Facility facilitates collaborative research among members of the MCC through the optimal application of informatics technologies and methods that maximize the accessibility and usability of data, information, and knowledge for cancer research. The primary goal of CRI is to provide comprehensive and centralized data acquisition and informatics support that is readily available to cancer center members.
The Specific Aims of the CRI are to: 1. Develop and support innovative technologies for funded research studies that facilitate accurate, timely, and secure data acquisition and dissemination. 2. Maintain and support a comprehensive patient-centered data warehouse offering unique opportunities for MCC investigators to utilize integrated data sets from diverse sources ranging from genetic biomarkers to population-based surveillance data. 3. Facilitate rapid and efficient recruitment of patients to investigator-initiated trials and other research studies. 4. Facilitate investigator access to data, biospecimens, and patients from Kentucky's Appalachian population. 5. Ensure the interoperability of informatics systems in compliance with evolving data standards. 6. Collaborate with the University of Kentucky (UK) Division of Biomedical Informatics to provide novel and state-of-the-art informatics solutions that increase the efficiency and accuracy of information and knowledge derived from diverse data sources.
The CRI is a critical resource supporting the acquisition, storage, management and utilization of data, information, and knowledge. The CRI integrates data from population, clinical, and research sources to identify and recruit study participants, annotate biospecimens, and derive unique research datasets for MCC investigators. This shared resource provides value-added service to MCC members, which has led to numerous publications and research grants from the NCI and other funding agencies.
|Gedaly, Roberto; De Stefano, Felice; Turcios, Lilia et al. (2018) mTOR Inhibitor Everolimus in Regulatory T cell Expansion for Clinical Application in Transplantation. Transplantation :|
|Pi, Fengmei; Binzel, Daniel W; Lee, Tae Jin et al. (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82-89|
|Wang, Qingding; Zhou, Yuning; Rychahou, Piotr et al. (2018) Deptor Is a Novel Target of Wnt/?-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth. Cancer Res 78:3163-3175|
|Rychahou, Piotr; Bae, Younsoo; Reichel, Derek et al. (2018) Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles. J Control Release 275:85-91|
|Kosmac, Kate; Peck, Bailey D; Walton, R Grace et al. (2018) Immunohistochemical Identification of Human Skeletal Muscle Macrophages. Bio Protoc 8:|
|Frohman, Heather A; Rychahou, Piotr G; Li, Jing et al. (2018) Development of murine bariatric surgery models: lessons learned. J Surg Res 229:302-310|
|Chaiswing, Luksana; St Clair, William H; St Clair, Daret K (2018) Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer. Antioxid Redox Signal 29:1237-1272|
|Chauhan, Aman; Farooqui, Zainab; Murray, Le Aundra et al. (2018) Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary. J Oncol 2018:3519247|
|Zhang, Xiaofei; Zhang, Yi; Han, Erik Y et al. (2018) Classification of Whole Mammogram and Tomosynthesis Images Using Deep Convolutional Neural Networks. IEEE Trans Nanobioscience 17:237-242|
|Li, Jing; Song, Jun; Li, Xian et al. (2018) FFAR4 Is Involved in Regulation of Neurotensin Release From Neuroendocrine Cells and Male C57BL/6 Mice. Endocrinology 159:2939-2952|
Showing the most recent 10 out of 359 publications